Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
Update on pythiosis immunobiology and immunotherapy
Érico S Loreto, Juliana SM Tondolo, Régis A Zanette, Sydney H Alves, Janio M Santurio, Department of Microbiology and Parasitology, Universidade Federal de Santa Maria, Santa Maria, RS 97105-900, Brazil
Érico S Loreto, Juliana SM Tondolo, Régis A Zanette, Sydney H Alves, Janio M Santurio, Programa de Pós-graduação em Ciências Farmacêuticas, Universidade Federal de Santa Maria, Santa Maria, RS 97105-900, Brazil
Author contributions: Loreto ÉS, Tondolo JSM, Zanette RA, Alves SH and Santurio JM solely contributed to this paper.
Supported by The Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brazil, No. CAPES-AUX PE-PNPD 743/2012
Correspondence to: Dr. Janio M Santurio, Department of Microbiology and Parasitology, Universidade Federal de Santa Maria, Av. Roraima nº 1000, Prédio 20, sala 4139, Santa Maria, RS 97105-900, Brazil. janio.santurio@gmail.com
Telephone: +55-55-32208906 Fax: +55-55-32208906
Received: March 27, 2014
Revised: May 6, 2014
Accepted: June 10, 2014
Published online: July 27, 2014
Revised: May 6, 2014
Accepted: June 10, 2014
Published online: July 27, 2014
Core Tip
Core tip: Pythiosis is a life-threatening disease for which there is no gold standard chemotherapy. Immunotherapy derived from killed mycelium from Pythium insidiosum is a non-invasive therapy that has demonstrated cure rates above 90% when associated with the surgical removal of the lesions and early disease diagnosis.